Szabados E - Search Results

1

The Effects of SGLT2 Inhibitors on Lipid Metabolism.

Szekeres Z, Toth K, Szabados E. Szekeres Z, et al. Among authors: szabados e. Metabolites. 2021 Feb 1;11(2):87. doi: 10.3390/metabo11020087. Metabolites. 2021. PMID: 33535652 Free PMC article. Review.

2

Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat.

Szabados E, Fischer GM, Toth K, Csete B, Nemeti B, Trombitas K, Habon T, Endrei D, Sumegi B. Szabados E, et al. Free Radic Biol Med. 1999 Feb;26(3-4):309-17. doi: 10.1016/s0891-5849(98)00199-3. Free Radic Biol Med. 1999. PMID: 9895221

3

The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals.

Habon T, Szabados E, Kesmarky G, Halmosi R, Past T, Sumegi B, Toth K. Habon T, et al. Among authors: szabados e. Cardiovasc Res. 2001 Oct;52(1):153-60. doi: 10.1016/s0008-6363(01)00359-5. Cardiovasc Res. 2001. PMID: 11557244

4

The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly(ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenol-damaged rat hearts.

Pálfi A, Tóth A, Kulcsár G, Hantó K, Deres P, Bartha E, Halmosi R, Szabados E, Czopf L, Kálai T, Hideg K, Sümegi B, Tóth K. Pálfi A, et al. Among authors: szabados e. J Pharmacol Exp Ther. 2005 Oct;315(1):273-82. doi: 10.1124/jpet.105.088336. Epub 2005 Jun 10. J Pharmacol Exp Ther. 2005. PMID: 15951400

5

PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.

Palfi A, Toth A, Hanto K, Deres P, Szabados E, Szereday Z, Kulcsar G, Kalai T, Hideg K, Gallyas F Jr, Sumegi B, Toth K, Halmosi R. Palfi A, et al. Among authors: szabados e. J Mol Cell Cardiol. 2006 Jul;41(1):149-59. doi: 10.1016/j.yjmcc.2006.03.427. Epub 2006 May 23. J Mol Cell Cardiol. 2006. PMID: 16716347

6

PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.

Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, Szabados E, Kálai T, Hideg K, Halmosi R, Sumegi B, Toth K. Bartha E, et al. Among authors: szabados e. Cardiovasc Res. 2009 Aug 1;83(3):501-10. doi: 10.1093/cvr/cvp144. Epub 2009 May 14. Cardiovasc Res. 2009. PMID: 19443425

7

Use of octreotide in the treatment of chylopericardium.

Szabados E, Toth K, Mezosi E. Szabados E, et al. Heart Lung. 2011 Nov-Dec;40(6):574-5. doi: 10.1016/j.hrtlng.2010.01.004. Epub 2010 Jun 4. Heart Lung. 2011. PMID: 20561867

8

Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.

Bartha E, Solti I, Szabo A, Olah G, Magyar K, Szabados E, Kalai T, Hideg K, Toth K, Gero D, Szabo C, Sumegi B, Halmosi R. Bartha E, et al. Among authors: szabados e. J Cardiovasc Pharmacol. 2011 Oct;58(4):380-91. doi: 10.1097/FJC.0b013e318225c21e. J Cardiovasc Pharmacol. 2011. PMID: 21697725

9

Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease.

Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, Battyany I, Sumegi B, Toth K, Szabados E. Magyar K, et al. Among authors: szabados e. Clin Hemorheol Microcirc. 2012;50(3):179-87. doi: 10.3233/CH-2011-1424. Clin Hemorheol Microcirc. 2012. PMID: 22240353 Clinical Trial.

10

Cardiac arrest in kearns-sayre syndrome.

van Beynum I, Morava E, Taher M, Rodenburg RJ, Karteszi J, Toth K, Szabados E. van Beynum I, et al. Among authors: szabados e. JIMD Rep. 2012;2:7-10. doi: 10.1007/8904_2011_32. Epub 2011 Sep 6. JIMD Rep. 2012. PMID: 23430846 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters